Drug-induced acute kidney injury in neonates

Current Opinion in Pediatrics

Volumn 28, Issue 2, 2016, Pages 180-187

  Hanna, Mina H ^a   Askenazi, David J ^b   Selewski, David T ^c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

acyclovir; aminoglycosides; amphotericin B; ibuprofen; nephrotoxic medication; nonsteroidal anti inflammatory drugs; vancomycin

Indexed keywords

ACICLOVIR; AMINOGLYCOSIDE; AMPHOTERICIN B; AMPICILLIN; ANTIINFECTIVE AGENT; BERACTANT; CAFFEINE CITRATE; CALFACTANT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE; FENTANYL; FUROSEMIDE; GENTAMICIN; INDOMETACIN; MIDAZOLAM; NONSTEROID ANTIINFLAMMATORY AGENT; SALBUTAMOL; VANCOMYCIN;

ACUTE KIDNEY FAILURE; CHRONIC KIDNEY DISEASE; CRITICALLY ILL PATIENT; DRUG INDUCED DISEASE; HUMAN; NEPHROTOXICITY; NEWBORN DISEASE; PREMATURITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; ACUTE KIDNEY INJURY; CHEMICALLY INDUCED; NEWBORN;

ACUTE KIDNEY INJURY; ACYCLOVIR; AMINOGLYCOSIDES; AMPHOTERICIN B; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; INFANT, NEWBORN; VANCOMYCIN;

EID: 84960467565     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0000000000000311     Document Type: Review

References (68)

1. Selewski DT, Charlton JR, Jetton JG, et al. Neonatal acute kidney injury. Pediatrics 2015; 136:e463-e473.
2. Askenazi DJ, Griffin R, McGwin G, et al. Acute kidney injury is independently associated with mortality in very low birthweight infants: a matched casecontrol analysis. Pediatr Nephrol 2009; 24:991-997.
3. Gadepalli SK, Selewski DT, Drongowski RA, Mychaliska GB. Acute kidney injury in congenital diaphragmatic hernia requiring extracorporeal life support: an insidious problem. J Pediatr Surg 2011; 46:630-635.
4. Carmody JB, Swanson JR, Rhone ET, Charlton JR. Recognition and reporting of AKI in very low birth weight infants. Clin J Am Soc Nephrol 2014; 9:2036-2043.
5. Zwiers AJ, de Wildt SN, Hop WC, et al. Acute kidney injury is a frequent complication in critically ill neonates receiving extracorporeal membrane oxygenation: a 14-year cohort study. Crit Care 2013; 17:R151.
6. Koralkar R, Ambalavanan N, Levitan EB, et al. Acute kidney injury reduces survival in very low birth weight infants. Pediatric Res 2011; 69:354-358.
7. Blinder JJ, Goldstein SL, Lee VV, et al. Congenital heart surgery in infants: effects of acute kidney injury on outcomes. J Thorac Cardiovasc Surg 2012; 143:368-374.
8. Jetton JG, Askenazi DJ. Update on acute kidney injury in the neonate. Curr Opinion Pediatr 2012; 24:191-196.
9. Morgan CJ, Zappitelli M, Robertson CM, et al. Risk factors for and outcomes of acute kidney injury in neonates undergoing complex cardiac surgery. J Pediatr 2013; 162:120-127.
10. Askenazi DJ, Ambalavanan N, Hamilton K, et al. Acute kidney injury and renal replacement therapy independently predict mortality in neonatal and pediatric noncardiac patients on extracorporeal membrane oxygenation. Pediatric Crit Care Med 2011; 12:e1-e6.
11. Selewski DT, Jordan BK, Askenazi DJ, et al. Acute kidney injury in asphyxiated newborns treated with therapeutic hypothermia. J Pediatr 2013; 162:725-729.
12. Oliveira JF, Silva CA, Barbieri CD, et al. Prevalence and risk factors for aminoglycoside nephrotoxicity in intensive care units. Antimicrob Agents and Chemother 2009; 53:2887-2891.
13. Andreoli SP. Acute kidney injury in children. Pediatr Nephrol 2009; 24:253-263.
14. Moffett BS, Goldstein SL. Acute kidney injury and increasing nephrotoxic medication exposure in noncritically-ill children. Clin J Am Soc Nephrol 2011; 6:856-863.
15. Goldstein SL, Kirkendall E, Nguyen H, et al. Electronic health record identification of nephrotoxin exposure and associated acute kidney injury. Pediatrics 2013; 132:e756-e767.
16. Zappitelli M, Moffett BS, Hyder A, Goldstein SL. Acute kidney injury in noncritically ill children treated with aminoglycoside antibiotics in a tertiary healthcare centre: a retrospective cohort study. Nephrology Dial Transplant 2011; 26:144-150.
17. Downes KJ, Rao MB, Kahill L, et al. Daily serum creatinine monitoring promotes earlier detection of acute kidney injury in children and adolescents with cystic fibrosis. J Cyst Fibros 2014; 13:435-441.
18. Cuzzolin L, Fanos V, Pinna B, et al. Postnatal renal function in preterm newborns: a role of diseases, drugs and therapeutic interventions. Pediatr Nephrol 2006; 21:931-938.
19. Suzuki M. Children's toxicology from bench to bed-Drug-induced renal injury (4): effects of nephrotoxic compounds on fetal and developing kidney. J Toxicol Sci 2009; 34 (Suppl 2):S267-S271.
20. Zaffanello M, Bassareo PP, Cataldi L, et al. Long-term effects of neonatal drugs on the kidney. J Matern Fetal Neonatal Med 2010; 23 (Suppl 3):87-89.
21. Laughon MM, Avant D, Tripathi N, et al. Drug labeling and exposure in neonates. JAMA Pediatr 2014; 168:130-136.
22. Hsieh EM, Hornik CP, Clark RH, et al. Medication use in the neonatal intensive care unit. Am J Perinatol 2014; 31:811-821.
23. Rhone ET, Carmody JB, Swanson JR, Charlton JR. Nephrotoxic medication exposure in very low birth weight infants. J Matern Fetal Neonatal Med 2014; 27:1485-1490.
24. Kimberlin DW, Lin CY, Jacobs RF, et al. Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics 2001; 108:230-238.
25. Rao S, Abzug MJ, Carosone-Link P, et al. Intravenous acyclovir and renal dysfunction in children: a matched case control study. J Pediatr 2015; 166:1462-1468.
26. Becker BN, Schulman G. Nephrotoxicity of antiviral therapies. Curr Opin Nephrol Hypertens 1996; 5:375-379.
27. Gunness P, Aleksa K, Bend J, Koren G. Acyclovir-induced nephrotoxicity: the role of the acyclovir aldehyde metabolite. Transl Res 2011; 158:290-301.
28. Vomiero G, Carpenter B, Robb I, Filler G. Combination of ceftriaxone and acyclovir - an underestimated nephrotoxic potential? Pediatr Nephrol 2002; 17:633-637.
29. Steinberg I, Kimberlin DW. Acyclovir dosing and acute kidney injury: deviations and direction. J Pediatr 2015; 166:1341-1344.
30. Hagos Y, Wolff NA. Assessment of the role of renal organic anion transporters in drug-induced nephrotoxicity. Toxins 2010; 2:2055-2082.
31. Kent A, Turner MA, Sharland M, Heath PT. Aminoglycoside toxicity in neonates: something to worry about? Expert Rev Anti Infect Ther 2014; 12:319-331.
32. Zappitelli MSD, Askenazi DJ. Nephrotoxic medication exposure and acute kidney injury in neonates. Neoreviews 2012; 13:e420-e427.
33. Mingeot-Leclercq MP, Tulkens PM. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother 1999; 43:1003-1012.
34. Allegaert K, Cossey V, van den Anker JN. Dosing guidelines of aminoglycosides in neonates: a balance between physiology and feasibility. Curr Pharm Des 2015; 21:5699-5704.
35. Jansen D, Peters E, Heemskerk S, et al. Tubular injury biomarkers to detect gentamicin-induced acute kidney injury in the neonatal intensive care unit. Am J Perinatol 2015; doi: 10.1055/s-0035-1563714. [Epub ahead of print]
36. McWilliam SJ, Antoine DJ, Sabbisetti V, et al. Mechanism-based urinary biomarkers to identify the potential for aminoglycoside-induced nephrotoxicity in premature neonates: a proof-of-concept study. PloS One 2012; 7:e43809.
37. Rao SC, Srinivasjois R, Hagan R, Ahmed M. One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates. The Cochrane Database Syst Rev 2011; CD005091.
38. Hamill RJ. Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs 2013; 73:919-934.
39. Manzoni P, Galletto P, Rizzollo S, et al. Liposomal amphotericin B does not induce nephrotoxicity or renal function impairment in premature neonates. Early Hum Dev 2012; 88 (Suppl 2):S86-S91.
40. Karadag-Oncel E, Ozsurekci Y, Yurdakok M, Kara A. Is liposomal amphotericin B really safety in neonates? Early Hum Dev 2013; 89:35-36.
41. Scarcella A, Pasquariello MB, Giugliano B, et al. Liposomal amphotericin B treatment for neonatal fungal infections. Pediatr Infec Dis J 1998; 17:146-148.
42. Goldman RD, Koren G. Amphotericin B nephrotoxicity in children. J Pediatr Hematol Oncol 2004; 26:421-426.
43. Harbarth S, Pestotnik SL, Lloyd JF, et al. The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 2001; 111:528-534.
44. Turcu R, Patterson MJ, Omar S. Influence of sodium intake on amphotericin Binduced nephrotoxicity among extremely premature infants. Pediatric Nephrol 2009; 24:497-505.
45. Bullo M, Tschumi S, Bucher BS, et al. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension 2012; 60:444-450.
46. Nadeem S, Hashmat S, Defreitas MJ, et al. Renin-angiotensin system blocker fetopathy: a midwest pediatric nephrology consortium report. J Pediatr 2015; 167:881-885.
47. Gantenbein MH, Bauersfeld U, Baenziger O, et al. Side effects of angiotensin converting enzyme inhibitor (captopril) in newborns and young infants. J Perinat Med 2008; 36:448-452.
48. Antonucci R, Zaffanello M, Puxeddu E, et al. Use of nonsteroidal antiinflammatory drugs in pregnancy: impact on the fetus and newborn. Curr Drug Metab 2012; 13:474-490.
49. Fanos V, Marcialis MA, Bassareo PP, et al. Renal safety of Non Steroidal Anti Inflammatory Drugs (NSAIDs) in the pharmacologic treatment of patent ductus arteriosus. J Matern Fetal Neonatal Med 2011; 24(Suppl 1): 50-52.
50. Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database Syst Rev 2015; 2:CD003481.
51. Neumann R, Schulzke SM, Buhrer C. Oral ibuprofen versus intravenous ibuprofen or intravenous indomethacin for the treatment of patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. Neonatology 2012; 102:9-15.
52. Bhatt-Mehta V, Schumacher RE, Faix RG, et al. Lack of vancomycin-associated nephrotoxicity in newborn infants: a case-control study. Pediatrics 1999; 103:e48.
53. Constance JE, Balch AH, Stockmann C, et al. A propensity-matched cohort study of vancomycin-associated nephrotoxicity in neonates. Arch Dis Child Fetal Neonatal Ed 2015; doi: 101136/archdischild-2015-308459. [Epub ahead of print]
54. Elyasi S, Khalili H, Dashti-Khavidaki S, Mohammadpour A. Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol 2012; 68:1243-1255.
55. McKamy S, Hernandez E, Jahng M, et al. Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. J Pediatr 2011; 158:422-426.
56. Burgess LD, Drew RH. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam. Pharmacotherapy 2014; 34:670-676.
57. Fauconneau B, Favreliere S, Pariat C, et al. Nephrotoxicity of gentamicin and vancomycin given alone and in combination as determined by enzymuria and cortical antibiotic levels in rats. Ren Fail 1997; 19:15-22.
58. White SL, Perkovic V, Cass A, et al. Is low birth weight an antecedent of CKD in later life? A systematic review of observational studies. AM J Kidney Dis 2009; 54:248-261.
59. Carmody JB, Charlton JR. Short-term gestation, long-term risk: prematurity and chronic kidney disease. Pediatrics 2013; 131:1168-1179.
60. Faa G, Gerosa C, Fanni D, et al. Marked interindividual variability in renal maturation of preterm infants: lessons from autopsy. J Matern Fetal Neonatal Med 2010; 23(Suppl 3):129-133.
61. Rodriguez MM, Gomez AH, Abitbol CL, et al. Histomorphometric analysis of postnatal glomerulogenesis in extremely preterm infants. Pediatr Dev Pathol 2004; 7:17-25.
62. Sutherland MR, Gubhaju L, Moore L, et al. Accelerated maturation and abnormal morphology in the preterm neonatal kidney. J Am Soc Nephrol 2011; 22:1365-1374.
63. Brenner BM, Garcia DL, Anderson S. Glomeruli and blood pressure. Less of one, more the other? Am J Hypertens 1988; 1:335-347.
64. Basile DP. The endothelial cell in ischemic acute kidney injury: implications for acute and chronic function. Kidney Int 2007; 72:151-156.
65. Askenazi DJ, Feig DI, Graham NM, et al. 3-5 year longitudinal follow-up of pediatric patients after acute renal failure. Kidney Int 2006; 69:184-189.
66. Mammen C, Al Abbas A, Skippen P, et al. Long-term risk of CKD in children surviving episodes of acute kidney injury in the intensive care unit: a prospective cohort study. Am J Kidney Dis 2012; 59:523-530.
67. Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int 2012; 81:442-448.
68. Abitbol CL, Bauer CR, Montane B, et al. Long-term follow-up of extremely low birth weight infants with neonatal renal failure. Pediatr Nephrol 2003; 18:887-893.